-
Today15/12/2024
Utilities
- indicates CPV codes deduced from the text of the procedure
- indicates text translated automatically in your browsing language
Acquisition of onasemnogen abeparvovec solution for infusion (Zolgensma® 2x10exp13 vector genomes/ml solution for infusion) Text automatically translated in your browsing language Automatically translated
Onasemnogen abeparvovec for SmPC use in patients with 5q spinal muscular atrophy (SMA) with a SMN1 gene biallelic mutation and clinical diagnosis of type 1 SMA, or - 5q spinal muscular atrophy (SMA) with a SMN1 gene biallelic mutation and up to 3 copies of the SMN2 gene. Text automatically translated in your browsing language Automatically translated
33600000 - Pharmaceutical products
33630000 - Medicinal products for dermatology and the musculo-skeletal system CVP code deduced from the text of the procedure AI-generated
33632000 - Medicinal products for the musculo-skeletal system CVP code deduced from the text of the procedure AI-generated
Type: cost
Description: Arvioidun kokonaiskulutuksen yhteenlasketut kustannukset.
Weight (percentage, exact):
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.